AU730295B2

AU730295B2 - Triaryl substituted imidazoles as glucagon antagonists

Info

Publication number: AU730295B2
Application number: AU54428/98A
Authority: AU
Inventors: Linda L. Chang
Original assignee: Merck and Co Inc
Current assignee: Merck and Co Inc
Priority date: 1996-11-20
Filing date: 1997-11-17
Publication date: 2001-03-01
Anticipated expiration: 2017-11-17
Also published as: WO1998022109A1; CA2271893A1; EP0959886A4; JP2000514088A; AU5442898A; EP0959886A1

Description

WO 98/22109 PCTIUS97/21020 -1- TITLE OF THE INVENTION TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON

ANTAGONISTS

BACKGROUND OF THE INVENTION The present invention relates to triaryl substituted imidazoles which antagonize the metabolic effect of glucagon. This invention also relates to compositions containing such compounds and methods of treatment using such compounds.

Diabetes is a disease process derived from multiple causative factors and characterized by elevated levels of plasma glucose.

Uncontrolled hyperglycemia is associated with an increased risk for microvascular and macrovascular diseases, including nephropathy, retinopathy, hypertension, stroke and heart disease. Control of glucose homeostasis is, therefore, a major approach to the treatment of diabetes.

Glucagon is a major counter regulatory hormone that attenuates the inhibition of liver gluconeogenesis by insulin. Glucagon receptors are found primarily in the liver, although their presence has been documented in kidney, pancreas, adipose tissues, heart, smooth muscles of vascular tissues, and some regions of the brain, stomach and adrenal glands.

Type II diabetics have elevated levels of plasma glucagon and increased rates of hepatic glucose production. The rate of hepatic glucose production positively correlates with fasting blood glucose levels in type II diabetics. Therefore, antagonists of glucagon are useful in improving insulin responsiveness in the liver, decreasing the rate of gluconeogenesis and lowering the rate of hepatic glucose output resulting in a decrease in the levels of plasma glucose.

A monoclonal antibody to glucagon (Glu-mAb) has been utilized to test the acute effects of attenuation of glucagon action in streptozotocin-treated diabetic rats (Brand et al., Diabetologia 37:985, 1994). In contrast to a control antibody, injection of Glu-mAb attenuated the postprandial increase in blood glucose in moderately hyperglycemic rats rats with a moderate impairment in insulin secretion). In WO 98/22109 PCT/US97/21020 -2severely hyperglycemic rats rats with severely impaired insulin secretion), Glu-mAb injection did not lower blood glucose levels, but potentiated the hypoglycemic effect of a suboptimal dose of insulin.

These data suggest that attenuation of the action of glucagon in these models leads to increased sensitivity to the action of insulin, but does not lead to decreased blood glucose levels in the absence of insulin. On the other hand, a monoclonal antibody to glucagon was effective in lowering plasma glucose levels in diabetic rabbits independent of insulin effects (Brand et al., Diabetes, 45:1076 (1996). While these data support the notion that antagonism of glucagon action will provide beneficial therapy for both type I and type II diabetics, this hypothesis could be more rigorously tested if a specific non-peptidyl glucagon antagonist were available.

The regulation of glucagon homeostasis is also mediated by the hormone insulin, produced in the 0 cells of the pancreas.

Deterioration of these cells is typically observed in Type I diabetics, and abnormalities in the function of these cells may occur in patients presenting the symptoms of Type II diabetes. Thus, a glucagon antagonist might have utility in treating Type I diabetics.

The glucagon receptor is expressed in kidney tissues where glucagon has been demonstrated to have an effect on electrolyte homeostasis including the ions sodium, potassium, chloride, magnesium, calcium, and phosphate and the non-electrolytes urea and water (Ahloulay et al., Am. J. Physiol., 269: F225, 1995). A glucagon antagonist may have use in treating disorders involving electrolyte imbalance. The kidney is also gluconeogenic in response to glucagon (Amores et al., Molec. Cell Biochem., 137: 117, 1994) and an antagonist would act to lower glucose production in kidney furthering the treatment of diabetes.

Glucagon receptors are present in the heart and in smooth muscles. Glucagon has a direct effect on cardiac output and heart rate (Glick et al., Circ. Res., 22: 789 (1968); Farah, Pharm. Rev., 35: 181, 1983). A strong correlation has been observed in patients with hypertension and elevated plasma glucagon levels resulting from WO 98/22109 PCT/US97/21020 -3impaired hepatic catabolism (Silva et al., Heptatology, 11: 668, 1990).

Antagonism of the effects of elevelated glucagon levels may have an effect on certain types of hypertension, thus a glucagon antagonist may have utility in the treatment of certain types of hypertension associated with elevated glucagon production.

The primary role for glucagon and glucagon receptors associated with adipose tissues is to induce lipolysis, thus providing free fatty acids as a substrate for fat burning tissues (Saggerson et al., Biochem. 238: 387, 1986). An antagonist to this effect might be useful in treating conditions where there is excessive lipolysis of fat stores resulting from elevated glucagon levels, such as wasting disease (cachexia).

Glucagon and glucagon receptors have been localized to the hippocampus region of the brain (Hoosein and Gurd, Proc. Natl. Acad.

Sci. USA, 81: 4368, 1984). This discovery suggests that glucagon may have a neuroendocrine role in initiating or elaborating basic behavior or somatic motor programs. Since glucagon secretion is increased in response to low blood glucose levels, increased glucagon levels in the brain may initiate behavior to respond to low glucose levels, such as eating. Thus, chronic hyperglucagonemia may also result in a constant craving for food resulting in obesity. A glucagon antagonist may have utility in treating obesity by altering feeding behavior associated with a response to glucagon.

The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptors and thereby decrease the levels of plasma glucose. The instant compounds thus are useful as antidiabetic agents. Glucagon may have other direct effects on cardiac output, lipolysis, and feeding behavior and therefore may be useful as antihypertensive, anti-cachexia or antiobesity agents.

SUMMARY OF THE INVENTION The present invention relates to 2,4-diaryl-5-pyridyl imidazoles which are glucagon receptor antagonists. These compounds 4 are therefore useful for the treatment of diseases caused by excessive levels of glucagon, including diabetes and certain types of hypertension, cachexia and obesity.

Also included in the invention are pharmaceutical compositions which comprise a compound of formula I in combination with a pharmaceutically acceptable carrier.

Also included in the invention are methods of treating glucagon-mediated disease, comprising administering to a mammalian patient in need of such treatment an amount of a compound of formula I which is effective to treat said disease.

Still further included in the invention are the uses of a compound of formula I for the manufacture of a medicament for treating glucagon-mediated disease, particularly diabetes disease.

oo *o*oo *o *oo [RAULBAA1083 7.doc: kw to 8 This page has been left blank intentionally 9 a a a R:\L[BAA]O83 7Odoc: k-~ 9 Detailed Description of the Invention The present invention provides compounds of formula N3

N

H

wherein R, is 4-pyridyl or 4-quinolyl;

R

2 is phenyl which is unsubstituted or substituted with one, two or three substituents each of which is independently selected from the group consisting of [R:\LIBAA]08370.doc:kww WO 98/22109 PCT/US97/21020 R3 is phenyl Ci-10 alkyl, R4, and C1-10 alkyl substituted with up to 5 groups independently selected from R4; substituted with one or two substituents each of which is independently selected from the group consisting of C4-10 alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms, -O-C3-10 alkyl, -O-C1-2 alkylaryl, -S-C2-10 alkyl, meta -0-phenyl, which is optionally substituted with halo, C1-4 alkyl, or C1-4 alkoxy; R4 is (1) (2) R8 is selected from -OR8, halogen hydrogen, and R11; and R11 is Cl-10 alkyl, halo-substituted C 1 -10 alkyl, C3-7 cycloalkyl, aryl, aryl-Cl-10 alkyl, or a pharmaceutically acceptable salt thereof.

In a further preferred embodiment there are provided compounds of formula wherein R1 is 4-pyridyl; R2 is phenyl which is substituted with one or two substituents each of which is independently selected from the group consisting of CI-10 alkyl, R4, and CI-10 alkyl substituted with up to 5 groups independently selected from halogen WO 98/22109 WO 9822109PCTIUS97/21020 I1I- R3 is phenyl 'Substituted with one or two substituents each of which is independently selected from the group consisting of C4-10 alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms, -0-C3-10 alkyl, -0-C 1 -2 alkylaryl, -S-C2-10 alkyl, meta -0-phenyl, which is optionally substituted with halo, Cl1-4 alkyl, or C 1 -4 alkoxy; R4 is -0R8, halogen; R8 is Ril; RII is CI-10 alkyl, halo-substituted C 1- 10 alkyl, C3-7 cycloalkyl, aryl, aryl-C I -10 alkyl, or a pharmaceutically acceptable salt thereof.

Especially preferred compounds of formula I include: 2-(4-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4pyridyl)imidazole 2-(3-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4pyridyl)imidazole 2-(3,4-dichlorophenyl)-4-(3-phenoxyphenyl)-5-(4pyridyl)imidazole 2-(4-phenoxyphenyl)-4-(3-phenoxyphenyl)-5 pyridyl)imidazole 4-(4-n-butylphenyl)-2-(4-chlorophenyl)-5-(4pyridyl)imidazole 4-(4-n-butylphenyl)-2-(3-chlorophenyl)-5-(4pyridyl)imidazole 4-(4-t-butylphenyl)-2-(4-chlorophenyl)-5-(4pyridyl)imidazole WO 98/22109 WO 9822109PCT/US97/21020 12 4-(4-t-butylphenyl)-2-(3-chlorophenyl)-5-(4pyridyl)imidazole 2-(4-chlorophenyl)-4-(4-n-propyloxyphenyl)-5-(4pyridyl)imidazole (10) 2-(4-chlorophenyl)-4-(4-ethylthiophenyl)-5-(4pyridyl)imidazole (11) 4-(3-phenoxyphenyl)-5-(4-pyridyl)-2-(4trifluoromethylphenyl)-imidazole (12) 2-(4-bromophenyl)-4-(3-phenoxyphenyl)-5-(4pyridyl)imidazole (13) 2-(4-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4pyridyl)imidazole (14) 2-(4-benzyloxyphenyl)-4-(3-phenoxyphenyl)-5-(4pyridyl)imidazole (15) 2-(3-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4pyridyl)imidazole (16) 4-(3-n-butyloxyphenyl)-2-(4-chlorophenyl)-5-(4pyridyl)imidazole (17) 4-(2-n-butyloxyphenyl)-2-(4-chlorophenyl)-5 pyridyl)imidazole (18) 2-(4-chlorophenyl)-4-(2,4-di(n-propyloxy)phenyl)-5-(4pyridyl)iniidazole (19) 2-(4-chlorophenyl)-4-(2,4-di(n-butyloxy)phenyl)-5-(4pyridyl)imidazole (20) 4-(4-benzyloxyphenyl)-2-(4-chlorophenyl)-5-(4pyridyl)imidazole.

For the purposes herein of nomenclature, the compounds of formula I are named by their position corresponding to: 33 4

N

H

WO 98/22109 PCT/US97/21020 13- The invention is described herein in detail using the terms defined below unless otherwise specified.

"Halogen" includes fluorine, chlorine, bromine and iodine.

The term "alkyl" refers to a monovalent alkane (hydrocarbon)-derived radical containing the designated number of carbon atoms. It may be straight or branched. Examples include methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, sec-butyl, isopentyl and tbutyl.

The term "alkenyl" refers to a hydrocarbon radical, straight or branched, containing the designated number of carbon atoms and at least one carbon to carbon double bond. Preferably one carbon to carbon double bond is present, and up to four non-aromatic (non-resonating) carbon-carbon double bonds may be present. Examples of alkenyl groups include ethenyl, propenyl, butenyl and isobutenyl.

.The term "alkynyl" refers to a hydrocarbon radical, straight or branched, containing the designated number of carbon atoms and at least one carbon to carbon triple bond. Up to three carbon-carbon triple bonds may be present. Examples of alkynyl groups include ethynyl, propynyl and butynyl.

Aryl refers to aromatic rings including phenyl and naphthyl.

The term "heteroaryl" (on its own or in any combination, such as "heteroaryloxy") represents a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, 0 and S, such as, but not limited to pyridyl, pyrimidinyl, pyrrolyl, furyl, thienyl, imidazolyl, thiazolyl, thiadiazolyl, tetrazolyl, triazolyl, oxadiazolyl, oxazolyl, imidazolidinyl, pyrazolyl, isoxazolyl, benzothiadiazolyl, indolyl, indolinyl, benzodioxolyl, benzodioxanyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazinyl, benzisoxazolyl, benzothiazolyl, 2,3-dihydrobenzofuranyl, quinolinyl, isoquinolinyl, benzotriazolyl, benzoxazolyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, purinyl, furopyridine and thienopyridine, tetrahydrobenzothiazolyl, 5,6,7,8tetrahydroquinolinyl, 2,3-cyclopentenopyridyl, 4,5,6,7-tetrahydroindolyl, 5,6,7,8-tetrahydroisoquinolyl, and 5,6,7,8-tetrahydroquinoxalinyl.

WO 98/22109 PCT/US97/21020 14- "Heterocyclic" (on its own or in any combination, such as "heterocyclylalkyl") represents a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, 0 and S. Examples of heterocyclyls are piperidinyl, morpholinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydroimidazo[4,5-c]pyridine, imidazolinyl, piperazinyl, pyrazolindinyl and the like.

The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.

The compounds of the present invention may contain one or more asymmetric carbon atoms and may occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included within the scope of the present invention.

Throughout the instant application, the following abbreviations are used with the following meanings: Bu butyl Bn benzyl BOC, Boc t-butyloxycarbonyl BOP Benzotriazol-1 -yloxy tris/dimethylamino)phosphonium hexafluorophosphate CBZ, Cbz Benzyloxycarbonyl DCC Dicyclohexylcarbodiimide DCM dichloromethane DIEA diisopropylethylamine DMF N,N-dimethylformamide WO 98/22109 PCT/US97/21020

DMAP

DSC

DTT

EDC

Et EtOAc EtOH eq.

FAB-MS

HOAc

HPLC

HOBT, HOBt

H

KHMDS

LAH

LHMDS

Me MHz

MPLC

NMM

NMR

PBS

Ph

TFA

THF

TLC

TMS

4-Dimethylaminopyridine N,N'-disuccinimidyl carbonate dithiothreitol 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ethyl ethyl acetate ethanol equivalent(s) Fast atom bombardment-mass spectroscopy acetic acid High pressure liquid chromatography Hydroxybenztriazole human serum Potassium bis(trimethylsilyl)amide Lithium aluminum hydride Lithium bis(trimethylsilyl)amide methyl Megahertz Medium pressure liquid chromatography N-Methylmorpholine Nuclear Magnetic Resonance phosphate buffer saline phenyl Trifluoroacetic acid Tetrahydrofuran Thin layer chromatography Tetramethylsilane The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids/bases and organic acids/bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, WO 98/22109 PCT/US97/21020 -16potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

Salts derived from inorganic acids include hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids include acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of formula I which contain a basic or acidic moiety by conventional chemical methods.

Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

This invention relates to a method of inhibiting the action of glucagon at its receptors thereby reducing the rate of gluconeogenesis and the concentration of glucose in plasma. Thus, compounds of formula I can be used in the prophylaxis or treatment of disease states in mammals mediated by elevated levels of glucagon.

Examples of such disease states include diabetes, obesity, hypertension, and cachexia and the like.

WO 98/22109 PCT/US97/21020 17- The compounds of formula I are normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. This invention, therefore, also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier employed may be, for example, solid or liquid. Solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Liquid carriers include syrup, peanut oil, olive oil, water and the like. Similarly, the carrier may include time delay material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.

The compounds of formula I are administered in conventional dosage forms prepared by combining a compound of formula I with standard pharmaceutical carriers according to conventional procedures. The compounds of formula I may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

The active compounds of the present invention may be orally administered as a pharmaceutical composition, for example, with an inert diluent, or with an assimilable edible carrier, or they may be enclosed in hard or soft shell capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, which includes sublingual administration, these active compounds may be incorporated with excipients and used in the form of tablets, pills, capsules, ampules, sachets, elixirs, suspensions, syrups, and the like. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.

WO 98/22109 PCT/US97/21020 18- The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

These active compounds may also be administered parenterally, for example intravenously, intramuscularly, intradermally or subcutaneously. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.

In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

The compounds of formula I may also be administered topically in the form of a liquid, solid or semi-solid. Liquids include WO 98/22109 PCT/US97/21020 19 solutions, suspensions and emulsions. Solids include powders, poultices and the like. Semi-solids include creams, ointments, gels and the like.

Drops according to the present invention may comprise sterile aqueous or oil solutions or suspensions, and may be prepared by dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.

Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finelydivided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous liquid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or macrogels. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicas, and other ingredients such as lanolin may also be included.

Compounds of the present invention may also be administered intranasally as, for example, liquid drops or spray; by intranasal or oral inhalation; rectally; trasdermally; or vaginally.

WO 98/22109 PCT/US97/21020 20 The amount of a compound of formula I, for the methods of use disclosed herein, vary with the compound chosen, the mode of administration, the nature and severity of the condition being treated, and other factors left to the discretion of the physician. A representative dosing regimen for treating diabetes mellitus and/or hyperglycemia may involve administering a compound of formula I at a daily dosage of from about 0.001 milligram to about 100 milligram per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.07 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.

Compounds similar to Formula I have been described previously as cytokine inhibitors (W093/14081; W095/03297), antiinflammatory agents (W096/03387), and protein kinase inhibitors (W096/18626). None of these publications describe or claim treatment of diabetes by antagonism of the glucagon receptor by compounds of Formula I.

*Compounds of the present invention may be prepared by several general synthetic methods as described in, for example, M. R.

Grimmett, Comprehensive Heterocyclic Chemistry, The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds, A. R.

Katritzky and C. W. Rees, eds., Vol. 5, Pergamon Press, Oxford, 1984, pp. 457-498. The compounds of the present invention can be prepared by procedures illustrated in the accompanying schemes. The three general methods for preparation of the imidazole nucleus are outlined in Schemes 1 and 2.

In the first method (Scheme a suitably protected alcohol when RI is 4-pyridyl, is 4-(t-butyldimethylsilyloxymethylpyridine), is deprotonated with a strong base such as lithium diisopropyl amide or n-butyl lithium and the resulting anion is reacted with an appropriate N,O-dimethylhydroxamide to give a protected a-hydroxy ketone The protected a-hydroxy ketone is then condensed with a suitably functionalized aldehyde in WO 98/22109 PCT/US97/21020 -21 the presence of copper(II) acetate and ammonium acetate in acetic acid to form the desired compound Scheme 1.

Rj 1

"-OTBDMS

1 1. Base

O

2. MeN) R3 MeO 2

R

3

O

R, OTBDMS 3 SCu(OAc) 2

NH

4 0Ac HOAc 0 2 H R2 4

R

R, N R

H

In the second method (Scheme an heteroarylmethane (6) when RI is 4-pyridyl, is 4-picoline) is deprotonated with a strong base such as lithium diisopropyl amide or n-butyl lithium and the resulting anion is reacted with N,O-dimethylhydroxamide to give a ketone The dione is obtained by selenium dioxide oxidation of the ketone and then condensed with a suitably functionalized aldehyde in the presence of ammonium acetate in acetic acid to form the desired imidazole WO 98/22109 PCT/US97/21020 22 Scheme 2.

R

3 0 1. Base

R

1

-CH

3 O R 6 2. MeN R3 7 MeO 2 SeO 2 HOAc

R

R, N 4 R3 X R1 H R 2 NH 4 OAc R 0 HOAc 8 In the various synthetic methods described above, protection and deprotection of functional groups such as hydroxyl and amino groups may be required. The selection of the appropriate protecting groups, and methods for introducing and removing the protecting groups are within the knowledge of one skilled in the art, and are also described in standard reference books such as Greene and Wuts, Protective Groups in Organic Synthesis, 2d Ed., John Wiley Sons, Inc., 1991.

The following examples are provided to more fully illustrate the invention, and are not to be construed as limiting the scope of the invention in any manner.

EXAMPLE 1 4 -(4-t-Butylphenyl)-2-(4-chlorophenyl)-5-(4-p2yridyl)imidazole WO 98/22109 PCT/US97/21020 23

N

Cl Step A. 4-(t-Butyldimethylsilyloxy)methyl pyridine At room temperature, 10.9 g of 4-pyridylcarbinol (100 mmol) was treated with 60 mL of DCM followed by 21 mL (150 mmol) of triethylamine.

After being cooled to 10 18 g (120 mmol) of t-butyldimethylsilyl chloride (dissolved in 20 mL DCM) was added dropwise. The resulting reaction mixture was warmed to room temperature slowly and stirred overnight.

Subsequently, it was filtered over a pad of celite, rinsed with ether. Volatiles were removed and the residue was taken up in hexane and filtered over celite again, washed with hexane/ether, and the solvents removed by rotoevaporation.

This was repeated twice. Pumping under high vac of the residue thus obtained provided 22 g of the desired product as a light brown oil, mass spectrum (CI) m/e 224 Step B. 4-Pyridyl-t-butydimethylsilyloxymethyl 4-fluorophenyl ketone Into a 2 L 3-necked round bottom flask fitted with a thermometer, dry nitrogen gas inlet, addition funnel and mechanical stirrer wa added diisopropylamine (65 mL, 0.46 mol) in THF (120 mL). Cooled to -20 oC with a isopropyl alcohol/ dry ice bath and added a solution of n-butyllithium in hexanes (210 mL of a 2.5 M solution, 0.53 mol). Stirred at -15 oC for 30 min, then cooled to -20 oC. Added 4-t-butydimethylsilyloxymethylpyridine from Step A (98.2 g, 0.44 mol) neat over a 30 min period. Let stir for 45 min at oC. To this mixture was added a solution of 4-fluoro-N-methoxy-N-methylbenzamide (84.5 g, 0.46 mol) in THF (90 mL) over a 30 min period. The dark solution was stirred at 0 oC for 1 h, then warmed slowly to room temperature for 30 min. The reaction was poured into water (500 mL) containing ammonium chloride (100 After stirring for 10 min at room temperatue, the WO 98/22109 PCT/US97/21020 -24solution was extracted with ethyl acetate (3 times). The combined organic extracts were washed successively with water and saturated salt solution. The combined aqueous layers were extracted with ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 15-50% ethyl acetate in hexanes (17 L in total). The solvent was removed by rotoevaporation to yield the title compound as an amber oil (120.4 g, 74% yield).

Step C: 4-Pyridyl-t-butvydimethylsilyloxymethyl 4-t-butylphenyl ketone To a cooled solution of diisopropylamine (183 mg, 1.81 mmol) in dry THF (0.35 mL) at -20 oC was added a solution of n-butyllithium in hexanes (0.83 mL of a 2.5 M solution, 2.08 mmol). Stirred at -20 oC for 1 hr and then added a solution of 4-pyridyl-t-butydimethylsilyloxymethyl 4fluorophenyl ketone from Step B (383 mg, 1.72 mmol) in THF (0.45 mL).

Stirred at -20 oC for 45 min, resulting in a thick yellow-brown solution. A solution of 4-t-butyl-N-methoxy-N-methyl-benzamide (400 mg, 1.81 mmol) in THF (0.5 mL) was added and the solution stirred at -20 to 0 oC for 5 h. The reaction was cooled to -20 oC and quenched by the addition of a saturated ammonium chloride solution. The reaction mixture was then extracted with ethyl acetate (3 times) and the combined extracts washed successively with water (2 times) and saturated salt solution and dried over anhydrous sodium sulfate. The mixture was filtered and the solvent removed by rotoevaporation.

The residue was purified by flash column chromatography on silica gel eluted with 5-10% ethyl acetate in hexanes to yield the title compound as a yellow oil (341 mg, 49% yield).

Step D: 4 -(4-t-Butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole A solution of 4-pyridyl-t-butydimethylsilyloxymethyl 4-tbutylphenyl ketone from Step C (170 mg, 0.44 mmol), copper (II) acetate (161 mg, 0.89 mmol), ammonium acetate (342 mg, 4.44 mmol) and 4chlorobenzaldehyde (78 mg, 0.56 mmol) in acetic acid (3 mL) was heated to 110 C for 5 h. The reaction mixture was then cooled to 0 oC and ice (4 g), WO 98/22109 PCTIUS97/21020 25 ethyl acetate (4 mL) and concentrated ammonium hydroxide solution (4 mL) were added. After stirring for 30 min, the phases were separated and the aqueous layer extracted with ethyl acetate (2 times). The combined organic phases were successively washed with water (2 times) and saturated salt solution and dried over anhydrous sodium sulfate. The mixture was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 0-3% methanol in methylene chloride to yield the title compound as a pale yellow solid 102 mg, 59% yield), mass spectrum (CI) m/e 388 The following compounds were prepared by methods analogous to those described in Example 1 except the appropriately substituted N-methoxy-Nmethylbenzamide and substituted benzaldehyde was used in place of 4-t-butyl- N-methoxy-N-methylbenzamide and 4-chlorobenzaldehyde, respectively.

2-(4-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e 424 2-(3-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e 424 2-(3,4-dichlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e 458 (M+1) 2-(4-phenoxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e 482 (M+1) 4-(4-n-butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e 388 4-(4-n-butylphenyl)-2-(3-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e 388 WO 98/22109 WO 98/2 109PCT/US97/21020 26 4 4 -t-butylphenyl)-2-(3-chlorophenyl)-5-(4-pyriciyl)imidazole, mass spectrum (CI) m/e 388 2 4 -chlorophenyl)-4-(4-n-propyloxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) nile 390 2 -(4-chlorophenyl)-4-(4-ethylthiophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) mle 392 4-(3-phenoxyphenyl)-5-(4-pyridyl)-2-(4-trifluoromethylphenyl).

imidazole, mass spectrum (CI) m/e 458 2-(4-bromophenyl)-4-(3-phenoxyphenyl)-5 -(4-pyridyl)imidazole, mass spectrum (CI) nile =468, 470 2-(4-fl~uorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) mle 408 2-(4-benzyloxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) nile 496 (M+1 2-(3-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e 408 4-(3-n-butyloxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e 404 4-(2-n-butyloxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) nie 404 4-(4-benzyloxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e 438 (M+1) 4 EXAMPLE 2 WO 98/22109 PCT/US97/21020 27 2 -(4-chlorophenyl)-4-(2,4-di(n-propyloxy)phenyl)-5-(4-pyridyl)imidazole 0

N

N, N Cl Step A: 2.4-dihydroxy-N-methoxy-N-methyl-benzamide To a cooled solution of 2,4-dihydroxybenzoic acid (8 g, 52 mmol), N,O-dimethylhydroxylamine hydrochloride (6.1 g, 62 mmol) and Nmethylmorpholine (13.18 g, 130 mmol) in methylene chloride (50 mL) at 0 oC was added EDC batchwise (11.95 g, 62.3 mmol). Stirred at room temperature for 3 days. The reaction was quenched by the addition of water and then extracted with methylene chloride (2 times). The combined organic extracts were successively washed with a 10% aqueous citric acid solution, a sodium bicarbonate solution, water and saturated salt solution and dried over anhydrous sodium sulfate. The mixture was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 0-33% ethyl acetate in hexanes to yield the title compound, mass spectrum (CI) m/e 198 Step B: 2.4-Di-n-propyloxy-N-methoxy-N-methyl-benzamide To a solution of 2,4-dihydroxy-N-methoxy-N-methyl-benzamide (250 mg, 1.27 mmol) in DMF (1 mL) was added solid potassium carbonate (351 mg, 2.54 mmol) and 1-bromopropane (343 mg, 2.79 mmol). The reaction mixture was stirred overnight at 55 oC. The reaction was quenched by the addition of an aqueous solution of 10% citric acid. The mixture was extracted with ethyl acetate (2 times). The combinded organic extracts were successively washed with water and saturated salt solution and dried over anhydrous sodium sulfate. The mixture was filtered and the solvent removed by rotoevaporation.

The residue was purified by flash column chromatography on silica gel eluted WO 98/22109 PCT/US97/21020 28 with 0-50% ethyl acetate in hexanes to give the title compound, mass spectrum (CI) m/e 282 Step C: 2,4-Di-n-propyloxyphenyl 4-pyridylmethyl ketone To a cooled solution of lithium diisopropylamide (generated from diisopropylamine (109 mg, 1.07 mmol) and a solution of n-butyllithium in hexanes (0.49 mL of a 2.5 M solution, 1.22 mmol)) in THF (0.5 mL) at -78 oC was added 4-picoline (95 tL, 0.98 mmol). Stirred -78 to 0 oC for 1 h. The reaction mixture was cooled to -78 oC and a solution of 2,4-di-n-propyloxy-Nmethoxy-N-methyl-benzamide from Step B (274 mg, 0.98 mmol) in THF mL) was added dropwise. The reaction was stirred 0 oC for 4 h and then quenched by the addition of a saturated aqueous solution of ammonium chloride. The mixture was extracted with ethyl acetate (2 times). The combined extracts were successively washed with water and saturated salt solution and dried over anhydrous sodium sulfate. The solution was filtered and the solvents removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 0-50% ethyl acetate in hexanes to yield the title compound (147 mg, 48% yield), mass spectrum (CI) m/e 314 Step D: 1-(2.4-Di-n-propyloxyphenyl)-2-(4-pyridyl)ethane- 1.2-dione To an oxygen-free solution of 2,4-di-n-propyloxyphenyl 4pyridylmethyl ketone (142 mg, 0.45 mmol) in acetic acid (3.4 mL) was added selenium dioxide (50.3 mg, 0.45 mmol). The reaction was stirred at 90 oC for 1 h, then cooled to 0 oC. The reaction was quenched by the addition of a solution of potassium carbonate until the pH 8. The mixture was then extracted with ethyl acetate 2 times) and the combined extracts successively washed with wvater and saturated salt solution and dried over anhydrous sodium sulfate. The solution was filtered and the solvent removed by rotoevaporation.

The residue was purified by flash column chromatography on silica gel eluted with 50% ethyl acetate in hexanes to yield the title compound as a sticky yellow gum (65 mg, 44% yield), mass spectrum (CI) m/e 328 WO 98/22109 PCT/US97/21020 29 Step E: 2-(4-Chlorophenyl)-4-(2.4-di(n-propyloxy)phenyl)-5-(4pyridyl)imidazole A solution of 1-(2,4-di-n-propyloxyphenyl)-2-(4-pyridyl)ethane-1,2dione from Step D (61 mg, 0.19 mmol), ammonium acetate (144 mg, 1.87 mmol) and 4-chlorobenzaldehyde (33 mg, 0.23 mmol) in acetic acid (1.5 mL) was heated to 100 oC for 3.5 h. After cooling to 0 oC, the ice ethyl acetate (2 mL) and a concentrated solution of ammonium hydroxide was added until the pH was 10. The layers were separated and the aqueous layer extracted with ethyl acetate. The combined organic extracts were successively washed with water and saturated salt solution and dried over anhydrous sodium sulfate.

The mixture was filtered and the solvent removed by rotoevaporation. The residue was purified by flash column chromatography on silica gel eluted with 0-3% methanol in methylene chloride to yield the title compound as a creamcolored solid (25 mg, 30% yield), mass spectrum (CI) m/e 448 The following compound was prepared by methods analogous to those described in Example 1 except in Step B, 1-bromobutane was substituted for 1bromopropane: 2-(4-chlorophenyl)-4-(2,4-di(n-butyloxy)phenyl)-5-(4pyridyl)imidazole, mass spectrum (CI) m/e 476 BIOLOGICAL ASSAYS The ability of compounds of the present invention to inhibit the binding of glucagon and the synthesis or the activity of cytokines can be determined by the following in vitro assays.

12 5 I-Glucagon Binding Screen with CHO/hGLUR Cells The reagents are prepared as follows: 1M o-Phenanthroline (Aldrich #32,005-6, MW 198.23)(prepare fresh): 198.2 mg/ml ethanol DTT (Sigma #D-9779, MW 154.2) (prepare fresh).

WO 98/22109 PCT/US97/21020 30 Protease Inhibitor Mix(100OX): 5 mg leupeptin 10 mg benzamidine mg bacitracin 5 mg soybean trypsin inhibitor per ml DMSO. Store aliquots at -20 C.

250 pM Human Glucagon (Peninsula #7165,MW 3480.62): Solubilize mg vial in 575 l 0.1N acetic acid.Store in aliquots at -20 C. Thus, 1 ld yields 1 pM final concentration in assay for non-specific binding.

Assay Buffer: 20 mM Tris, pH 7.8; 1 mM DTT; 3 mM ophenanthroline.

Assay Buffer w/ 0.1% BSA (for dilution of label only, therefore 0.01% final in assay): 10 l 10% BSA (heat-inactivated) 990 pl assay buffer 12 5 I-Glucagon (NEN #NEX-207, receptor-grade, 2200 Ci/mmol): Dilute to 50,000 cpm/25 pl in assay buffer w/ BSA.Thus, -50 pM final concentration in assay.

Harvesting of CHO/hGLUR Cells for Assay: 1. Remove media from confluent flask then rinse once each with PBS (Ca,Mg-free) and Enzyme-free Dissociation Fluid (Specialty Media, Inc.).

2. Add 10 ml Enzyme-free Dissoc. Fluid and hold for -4 min. at 37 C.

3. Gently tap cells free, triturate, take aliquot for counting and centrifuge remainder for 5 min. at 1000 rpm.

4. Resuspend pellet in assay buffer (no BSA) at 75000 cells per 100 pl.

Alternatively, membrane preparations from CHO/hGLUR cells can be used in place of whole cells at the same assay volume. Final protein concentration of membrane preparation is determined on a per batch basis.

WO 98/22109 PCT/US97/21020 -31 The determination of inhibition of glucagon binding is carried out by measuring the reduction of 1 12 5 -glucagon binding in the presence of compounds of Formula I. The assay is carried out in a 96-well box. The following reagents are combined: Assay Compound 250 pM 1251- CHO/hGLUR Buffer /Vehicle Glucagon Glucagon Cells Total 120 pL /5 pL 25 L 100 pL Binding +compound 120 pL 5 pL/- 25 pL 100 ptL NSB 120 pL /5 pL lpL 25 pL 100 pL NSB:non specific binding The box is incubated for 60 min. at 22 °C on a shaker at 275 rpm. The wells are filtered over pre-soaked polyethylimine(PEI)) GF/C filtermat using an Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20 mM Tris, pH 7.8 buffer. Count filters in Gammascintillation counter.

Claims

1. A compound having the formula (I) R3 N R, N R 2 I H (I) s wherein RI is 4-pyridyl or 4-quinolyl; R 2 is phenyl which is unsubstituted or substituted with one, two or three substituents each of which is independently selected from the group consisting of Ci-CIo alkyl, R 4 and CI-C 10 alkyl substituted with up to 5 groups independently selected from R 4 R 3 is phenyl substituted with one or two substituents each of which is independently selected from the group consisting of C 4 1 0 alkyl, wherein said alkyl is optionally substituted with from 1 to 15 halogen atoms, -O-C 3 10 alkyl, -O-CI- 2 alkylaryl, -S-C 2 10 alkyl, meta-0-phenyl which is optionally substituted with halo, Ci- 4 alkyl, or 20 C 1 4 alkoxy; R4 is -ORs, halogen, R 8 is selected from hydrogen, and R; and R 11 is C- 10 o alkyl, halo-substituted Ci-Clo alkyl, C 3 7 cycloalkyl, S(4) aryl, [R:\LIBAA]08370.doc:k-w 33 aryl-Ci-io alkyl, or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein RI is 4-pyridyl; R 2 is phenyl which is substituted with one or two substituents each of which is independently selected from the group consisting of Ci-Clo alkyl, R 4 and Ci- 1 o alkyl substituted with up to 5 groups independently selected from halogen R 3 is phenyl substituted with one or two substituents each of which is independently selected from the group consisting of C 4 10 alkyl, wherein said alkyl is optionally substituted with from 1 to halogen atoms, 0 15is -0-C 3 1 o alkyl, 00 O-CI- 2 alkylaryl, -S-C 2 10 alkyl, a meta-O-phenyl, which is optionally substituted with halo, Ci- 4 alkyl, or Ci- 4 alkoxy; R 4 is -ORs, halogen; R 8 is Ri1; R 11 is C 1 -CI 0 alkyl, halo-substituted Ci- 10 alkyl, C 3 7 cycloalkyl, aryl, aryl-CI-o alkyl, or a pharmaceutically acceptable salt thereof.

3. A compound of claim 1 selected from the group consisting of: 2-(4-chlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, 2-(3-chlorophenyl)-4-(3-phenoxyphenyl)-5-4-pyridyl)imidazole, 2-(3,4-dichlorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, S(4) 2-(4-phenoxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,

4-(4-n-butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, [R:\LIBAA]08370.doc:kww 34 4-(4-n-butylphenyl)-2-(3-chlorophenyl)-5-(4-pyridyl)imidazole, 4-(4-t-butylphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, 4-(4-t-butylphneyl)-2-(3-chlorophenyl)-5-(4-pyridyl)imidazole, 2-(4-chlorophenyl)-4-(4-N-propyloxyphenyl)-5-(4-pyridyl)imidazole, (10) 2-(4-chlorophenyl)-4-(4-ethylthiophenyl)-5-(4-pyridyl)imidazole, (11) 4-(3-phenoxyphenyl)-5-(4-pyridyl)-2-trifluoromethylphenyl)-imidazole, (12) 2-(4-bromophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, (13) 2-(4-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, (14) 2-(4-benzyloxyphenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, (15) 2-(3-fluorophenyl)-4-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, (16) 2-(4-chlorophenyl)-4-(3-n-butyloxyphenyl)-5-(4-pyridyl)imidazole, (17) 2-(4-chlorophenyl)-4-(2-n-butyloxyphenyl)-5-(4-pyridyl)imidazole, (18) 2-(4-chlorophenyl)-4-(2,4-di(n-propyloxy)phenyl)-5-(4-pyridyl)imidazole, (19) 2-(4-chlorophenyl)-4-(2,4-di(n-butyloxy)phenyl)-5-(4-pyridyl)imidazole, and *15 (20) 2-(4-chlorophenyl)-4-(4-benzyloxyphenyl)-5-(4-pyridyl)imidazole. 4. A process of preparing a 2,4-diaryl-5-pyridylimidazole derivative, the process being substantially as hereinbefore described in any of the schemes or examples substantially as hereinbefore described.

A 2,4-diaryl-5-pyridylimidazole derivative prepared by the process of claim 4. 20

6. A 2,4-diaryl-5-pyridlylimidzole derivative, substantially as hereinbefore described with reference to any one of the examples.

7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3, 5 or 6 and a pharmaceutically acceptable carrier.

8. A method for treating glucagon mediated disease in a mammal, which method 25 includes or consists of administering to said mammal an effective amount of at least one compound according to any one of claims 1 to 3, 5 or 6 or of a composition according to claim 7.

9. A compound according to any one of claims 1 to 3, 5, or 6 or a composition according to claim 7 when used in treating glucagon mediated disease.

10. A compound according to any one of claims 1 to 3, 5 or 6 or a composition according to claim 7 for use in treating glucagon mediated disease.

11. The use of a compound according to anyone of claims 1 to 3, 5 or 6 for the manufacture of a medicament for treating glucagon mediated disease. 0

12. A method for treating diabetes disease in a mammal, which method includes 3 or consists of administering to said mammal an effective amount of at least one [R:\LIBAA]08370,doc:kww [R:\LIBAA]08370,doc:kww compound according to any one of claims 1 to 3, 5 or 6 or of a composition according to claim 7.

13. A compound according to any one of claims 1 to 3, 5 or 6 or a composition according to claim 7 when used in treating diabetes disease.

14. A compound according to any one of claims 1 to 3, 5 or 6 or a composition according to claim 7 for use in treating diabetes disease. The use of a compound according to any one of claims 1 to 3, 5 or 6 for the manufacture of a medicament for treating diabetes disease. Dated 31 October, 2000 Merck Co., Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON *eeo [R:\L1BAA]OS37O.doc:kww